

CURRICULUM VITAE : Shabir A Madhi

Professor Shabir Madhi

Date of Birth: 28 November 1966

Nationality: South African

1. Most Recent Current and Past Work Positions:

- i). Executive Director: National Institute for Communicable Diseases, National Health Laboratory Service. (2011-Current)
- ii). Professor of Vaccinology; School of Pathology; Univ. of Witwatersrand (2008-current)
- iii). Chair: Department of Science and Technology/ National Research Foundation – Vaccine Preventable Diseases. (2008 -current)
- iv). Co-director: University of Witwatersrand/MRC Respiratory and Meningeal Pathogens Research Unit. (2007 -2013)
- v). Director: University of Witwatersrand/MRC Respiratory and Meningeal Pathogens Research Unit. (2007 -2013)
- vi). Honorary Consultant: Department of Paediatrics. (1997 -2005)

2. PROFESSIONAL QUALIFICATIONS

- 1990: Bachelor of Medicine and Bachelor of Surgery (MBBCh);
University of the Witwatersrand, Johannesburg
- 1996: Fellow College of Paediatrics (FCPaeds (SA)); College of Medicine of South Africa
- 1998: Masters in Medicine (MMed Paediatrics); University of the Witwatersrand,
Johannesburg
- 2001-2010: Sub-speciality registration - Critical Care Paediatrics. Health Professional Council
of South Africa
- 2003: PhD (Health Sciences); University of the Witwatersrand, Johannesburg.
- 2010: Sub-speciality registration – Infectious Diseases. Health Professional Council of South
Africa

3. MEMBERSHIP OF PROFESSIONAL BODIES/ASSOCIATIONS

- i). Member: South African Medical Association (1996-)
- ii). Fellow: College of South Africa (1997-)
- iii). Member: South African Paediatric Association (1997-)
- iv). Member: Critical Care Society of South Africa. (2002-2009)
- v). Member: Federation of Infectious Diseases Society of South Africa. (2002-)
- vi). Member: European Society of Paediatric Infectious Diseases (2003-)
- vii). Deputy-president: Southern African Society of Infectious Diseases (2008-2013)
- viii). Board member : International Scientific Committee – World Society of Paediatric
Infectious Diseases (2008-2013)
- ix). Board-member: World Society of Paediatric Infectious Diseases (2009)
- x). President: World Society of Paediatric Infectious Diseases (2010-2013)

- xi). Board Member: International Symposium for Pneumococci and Pneumococcal Diseases (2009-Current)
- xii). Member: Academy of Science of South Africa (2012-Current)
- xiii). International Scientific Committee Member of International Society of Infectious Diseases (2013-Current)
- xiv). Chair: International Scientific Committee of World Society of Paediatric Infectious Diseases (2013-Current)
- xv). President: Southern African Society of Infectious Diseases (2014-Current).

4. ACADEMIC DISTINCTIONS/FELLOWSHIPS

- 1989: University of Washington, St Louis, USA. Exchange student. (Full scholarship)
- 2000: Scholarship to attend: *Biostatistics course*: International Center of Diarrhoeal Diseases and Research and Development, Bangladesh, Nov 1999.
- 2001: Scholarship to attend: *1st Advanced Vaccinology Course*- Marcel Merieux Foundation Institute, Annecy, France, May- June 2000.

5. AWARDS

- 2001: Watkins-Pitchford prize. Award Re: Best contribution to the literature during the year 2000 by a member of the South African Institute for Medical Research staff of less than 10-year standing.
- 2004: Faculty Research Price for best Research Article.
- 2006: European Society for Infectious Diseases, Young Investigators Award.
- 2009. Special Fellowship Award- Past Alumni Invite to Celebrate the 10th Anniversary of the Advanced Vaccinology Course; Annecy; France May 22-25th 2009
- 2009. National Science and Technology Forum: TW Kambule Award: Senior Black Researcher over the past 5-10 years.
- 2010. NRF President's Award for: Transformation of the Science Cohort.
- 2010: Vice-Chancellors Award for Research. University of the Witwatersrand.
- 2011: National Research Foundation A2 rating.
- 2013: Medical Research Council: Life Time Achievement Award (Platinum Medal)

6. NATIONAL RESEARCH FOUNDATION RATING: Category A2 (Effective 2011)

7. OTHER INTERNATIONAL TEMPORARY APPOINTMENTS/ CONSULTANCIES

- 1998-2001: Temporary Consultant to World Health Organisation pneumonia-radiology working-group.

- 1998-2001: Temporary Consultant to World Health Organisation “Respiratory syncytial virus in developing countries” working group.
- 2001: International Faculty member of the “Global Health Course” program initiated by Department of Health, Finland.
- 2003: Temporary Consultant to World Health Organisation: Management of Acute Respiratory Tract Infections in Countries with a high Prevalence of HIV-1 Infection.
- 2003: Temporary Consultant to World Health Organisation: Reviewer of proposal for: “Alternate Schedules for Introducing the Pneumococcal Conjugate Vaccine into Developing Countries”.
- 2003: Temporary Consultant to World Health Organisation: “*Haemophilus influenzae* type b prevention in Sub-Saharan Africa”
- 2003: Technical advisor: Activities in Research and Development Necessary to Accelerate the Introduction of Pneumococcal Conjugate Vaccine Use in Developing Countries. GAVI PneumoADIP.
- 2005: Technical advisor: Introduction of Pneumococcal Conjugate Vaccine Use in Developing Countries. GAVI PneumoADIP (London; United Kingdom).
- 2006: Temporary consultant to NIH/NIAID: WHO Essential care and Prevention Meeting (Switzerland).
- 2007: Temporary consultant to WHO: Global Action Plan for Pneumonia (La Mainaz France, 3rd-5th March 2007)
- 2007: Temporary consultant to Gates Foundation: Pneumonia Consultation Meeting. (Seattle USA, 3-6th May 2007)
- 2007: Invited Participant (African Representative): Global Vaccine Safety Datanet Meeting (Annecy, France: 11-13th Sept 2007)
- 2007: Consultant/Faculty: Physicians Academy for Clinical and Management Excellence. 1st Pneumonia Working Group Conference. (Seoul; South Korea. 14-15th December 2007).
- 2008: Invited participant: Global Burden of Disease: Respiratory syncytial virus. (Edinburgh, Scotland: 28-29th January 2008).
- 2008: Temporary consultant WHO. Global Action Plan for Pneumonia. (Geneva, Switzerland: 25-27th February 2008).
- 2008: Technical Advisor: GAVI PneumoADIP (Rome, Italy: 10-11th March 2008)
- 2008: Faculty Member: Global Masterclass on Childhood Bacterial Respiratory Diseases. (Brussels; Belgium: 29-30th March 2008)
- 2009-current: Advisor: Supporting National Independent Immunization and Vaccine Advisory Committees: The SIVAC Initiative. 29th May 2009; Paris; France
- 2009: Temporary Consultant World Health Organisation: Meeting to review WHO recommendations for the management of diarrhoea and pneumonia in the context

of HIV infection in infants and children. 19-21 October, 2009; Geneva, Switzerland.

- 2009-2010: Technical advisor/Consultant: Pneumonia Etiology Research for Child Health (PERCH); Johns Hopkins Bloomberg School of Public Health. 8-10th Sep 2009; Washington DC, USA.
- 2011: Invited participant: Bill and Melinda Gates Foundation: Maternal Influenza Immunization: Evidence, Policy Consideration, and Action Plan Convening Gates. 1-3 June 2011. Hyatt Regency London; London.
- 2010-2011: Member: Scientific Monitoring Board: HIV Vaccine Trials Network (HVTN)
- 2012: Temporary consultant: Optimizing rotavirus immunization schedules. WHO Ad Hoc Expert Consultation on Rotavirus Vaccination Schedules. 13-14 February 2012. WHO, Geneva.
- 2013-Current: Member: Bill and Melinda Gates Foundation: Global Health Program Scientific Advisory Committee.
- 2013: Advisor: RSV Vaccines for Maternal Immunization. PATH. 11 July 2013. Washington DC.
- 2013: Participant. Measuring short and long-term vaccine impact of PCV. World Health Organisation. Crowne Plaza Hotel, in Geneva, Switzerland. 16-19 September, 2013.

8. SUPERVISION OF HIGHER DEGREES (EXCLUDING POST-DOCS)

Student Initials:	Years supervised	Degree	Date completed* /expected completion	Institution	Race	Gender	Nationality
D Ruffini	2	MMed	2001*	Univ Wits	W	F	SA
M Htay	2	MSc	2001*	Univ Wits	B	F	Burmese
G Sorours	2	MMed	2004*	Univ Wits	W	F	SA
C Ngwazi	3	MMed	2004*	Univ Wits	B	M	Congolese
H Ludewick	3	PhD	2007*	Univ Wits	C	M	SA
D Moore	1	MMed	2008*	Univ Wits	W	M	SA
C Cutland (PT)	6	PhD	2014	Univ Wits	W	F	SA
Z Ditse	2	MSc	2011*	Univ Wits	B	F	SA
K Lebogo	2	PhD	2013	Univ Wits	B	F	SA
M Mhlongo	4	PhD	2013*	Univ Wits	B	M	SA
Z Radebe	2	MSc	2011*	Univ Wits	B	F	SA
Z Makhari	1	MSc	2011*	Univ Wits	B	F	SA
O Simani	5	PhD	2014	Univ Wits	B	F	SA

Z Dangor (PT)	2	MMed	2012*	Univ Wits	I	M	SA
M Haupfleisch (PT)	2	MMed	2014*	Univ Wits	W	M	SA
S Chaya (PT)	2	MMed	2014	Univ Wits	I	F	SA
V Mammed (PT)	2	MMed	2014	Unit Wits	I	M	SA
C Cohen (PT)	3	PhD	2014	Univ Wits	W	F	SA
G Naidu (PT)	5	PhD	2014	Univ Wits	I	M	Indian
S Nzenze	5	PhD	2014	Univ Wits	B	F	Zim
M Groome (PT)	3	PhD	2014	Univ Wits	W	F	SA
Moore D	3	PhD	2014	Univ Wits	W	M	SA
Dangor Z	3	PhD	2014	Unit Wits	I	M	SA
Nteu K	3	MSc	2014	Univ Wits	B	F	SA
Chinyanganya L	2	MSc	2014	Unit Wits	B	F	Kenya
Olwagen C	2	MSc	2014	Univ Wits	W	F	SA
Dzanibe S	2	MSc	2014	Univ Wits	B	M	SA

9. RESEARCH OUTPUT

9.1 Peer-reviewed ACCREDITED JOURNALS

1. **Madhi SA**, Gray GE, Huebner RE, McKinnon D, Pettifor JM. Correlation between CD4+ lymphocyte counts, concurrent antigen skin test and tuberculin skin test reactivity in HIV-1 infected and uninfected children with tuberculosis. *Ped Infect Dis J*. 1999, 18: 800-805.
2. Klugman KP, **Madhi SA**. Emergence of drug resistance- impact on bacterial meningitis. *Infect Dis Clin North Amer* 1999, 13:637-646.
3. **Madhi SA**, Klugman KP. Pneumococcal conjugate vaccines- prospects for intervention in children. *Sem Resp Infect*. 1999, 14:285-294.
4. **Madhi SA**, Huebner RE, Doedens L, Aduc T, Wesley D, Cooper P. HIV-1 co-infection in children hospitalised with tuberculosis in South Africa. *Int J Tuberc Lung Dis* 2000; 4:448-454.
5. **Madhi SA**, Petersen K, Madhi A, Khoosal M, Klugman KP. Burden of disease and drug resistance of bacteria in HIV infected children with severe lower respiratory tract infections. *Clin Infect Dis*. 2000, 31:170-176.
6. **Madhi SA**, Schoub B, Simmank K, Blackburn N, Klugman KP. Increased burden of respiratory virus associated severe lower respiratory tract infections in HIV-1 infected children. *J Pediatr* 2000, 137: 78-84.
7. **Madhi SA**, Petersen K, Madhi A, Wasas A, Klugman KP. Impact of human immunodeficiency virus type-1 on the disease spectrum of *Streptococcus pneumoniae* in South African children. *Pediatr Infect Dis J* 2000, 19:1141-1147.
8. **Madhi SA**, Venter M, Madhi A, Petersen K, Klugman KP. Differing manifestation of respiratory syncytial virus associated severe lower respiratory tract infections in human

- immunodeficiency virus type-1 infected and uninfected children. *Pediatr Infect Dis J* 2001, 20:164-170.
9. **Madhi SA**, Madhi A, Petersen KM, Khoosal M, Klugman KP. The impact of human immunodeficiency virus type-1 infection on the epidemiology and outcome of bacterial meningitis in South African children. *Int J of Infect Dis*, 2001; 5:119-125.
 10. Venter M, **Madhi SA**, Tiemessen CT, Schoub BD. Genetic diversity and molecular epidemiology of respiratory syncytial virus over four consecutive seasons in South Africa: identification of new subgroup A and B genotypes. *J Gen Virology* 2001; 82:2117- 2124.
 11. **Madhi SA**. Childhood vaccination of the HIV-1 infected child. *SADentJ* 2001; 56: 610-3.
 12. **Madhi SA**. Lower respiratory tract infections in HIV-1 infected South African children. *SAJofHIVMed*. August 2001, 1(5): 32-39.
 13. Ruffini D, **Madhi SA**. The high burden of *Pneumocystis carinii* pneumonia in HIV-1 infected children hospitalised for severe pneumonia. *AIDS*. 2002; 16:105-112.
 14. **Madhi SA**; Petersen K, Huebner RE; Mbelle N; Khoosal M; Mothupi R; Saloojee H; Crewe-Brown H; Klugman KP. Reduced effectiveness of *Haemophilus influenzae* type b conjugate vaccine in children with a high prevalence of HIV-1 infection. *Pediatr Infect Dis J* 2002; 21: 315-21.
 15. **Madhi SA**, Ramasamy N, Besselaar TG, Klugman KP. Influenza A and B virus' associated lower respiratory tract infections in an area with a high prevalence of pediatric human immunodeficiency type-1 infection. *Pediatr Infect Dis J* 2002; 21: 300-307.
 16. **Madhi SA**, Cumin E, Klugman KP. Defining the potential impact of conjugate bacterial polysaccharide-protein vaccines in reducing the burden of pneumonia in human immunodeficiency virus type 1 infected and –uninfected children. *Pediatr Infect Dis J* 2002; 21: 393-9.
 17. Lala SG, **Madhi S A**, Pettifor JM. The discriminative value of C-reactive protein levels in distinguishing between community-acquired bacteraemic and respiratory virus-associated lower respiratory tract infections in HIV-1-infected and -uninfected children. *Ann Trop Paediatr* 2002; 22:271-9.
 18. **Madhi SA**, Petersen K, Madhi A, Klugman KP. Human parainfluenza virus 1-3 associated severe lower respiratory tract infections in human immunodeficiency virus type-1 infected and uninfected children. *Europ J Clin Microbiol Infect Dis* 2002; 21;499-505.
 19. **Madhi SA**, Cutland C, Ismail K, O'Reilly C, Mancha A, Klugman KP. Ineffectiveness of trimethoprim-sulfamethoxazole prophylaxis and importance of concurrent bacterial and respiratory viral co-infections among human immunodeficiency virus type-1 infected African children hospitalized with *Pneumocystis carinii* pneumonia. *Clin Infect Dis* 2002; 35:1120-6.
 20. **Madhi SA**, Radebe K, Crewe-Brown HH, Frasci C, Arakere G, Mokhachane M, Kimura A. Distribution of *Streptococcus agalactiae* and the high burden of invasive disease among South African Children. *Ann Trop Paediatr* 2003, 23:15-23.

21. **Madhi SA**, Venter M, Alexandra R, Lewis H, Kara Y, Karshagen, Greef M, Lassen C. Respiratory syncytial virus associated illness in high risk children and national characterisation of the circulating virus genotype in South Africa. *J Clin Virol* 2003; 27: 180-189.
22. **Madhi SA**. Use of bacterial-conjugate vaccines in HIV-1 infected children. *Current Allergy and Clinical Immunology*. 2003; 16 (3):53-59.
23. Abdool Karim S, Abdool Karim Q, Adhikari M, Cassol S, Chersich M, Cooper P, Coovadia A, Coovadia H, Cotton M, Coutoudis A, Hide W, Hussey G, Maartens G, **Madhi S**, Martin D, Pettifor JM, Rollins N, Sherman G, Thula S, Urban M, Velaphi S, Williamson C. Vertical HIV transmission in South Africa: translating research into policy and practice. *Letter: Lancet* 2002; 359:992-3
24. Klugman, K.P.; **Madhi S.A.**; Huebner R.E.; Kohberger R. Mbelle N; Pierce N and Vaccine trialist group. Prevention of pneumonia and invasive pneumococcal disease by a 9-valent pneumococcal conjugate vaccine: efficacy in both HIV – infected and uninfected children. *NEJM*. 2003; 349(14):1341-8.
25. **Madhi SA**. Vaccinating against *Streptococcus pneumoniae*- The new generation vaccine. *SA Resp. J*. 2002; 8:35-42.
26. **Madhi SA**, Ludewick H, Abed Y, Klugman KP, Boivin G. Human metapneumovirus associated lower respiratory tract infections among hospitalized HIV-1 infected and HIV-1 uninfected African infants. *Clin Infect Dis* 2003 37: 1705 - 1710.
27. **Madhi SA**, Ismail K, O'Reilly C, Cutland C. Importance of nosocomial respiratory syncytial virus infections in an African setting. *Trop Med Int Health*. 2004; 9:491-8.
28. Cotton M, Schaaf S, Hesselning A, **Madhi SA**. HIV and childhood tuberculosis - the way forward. *Int. J Tuberc and Lung Dis*. 2004; 8:675-82.
29. Brink AJ, Cotton MF, Feldman C, Geffen L, Hendson W, Hockman MH, Maartens G, **Madhi SA**, Mutua-Mpungu M, Swingler GH. Guideline for the management of upper respiratory tract infections. *S Afr Med J* 2004; 94: 475-483.
30. Buie KA, Klugman KP, von Gottberg A, Perovic O, Karstaedt A, Crewe-Brown H, **Madhi SA**, Feldman C. Gender as a Risk Factor for Antibiotic Resistance, Infection with Pediatric Serogroups and Pneumococcal Bacteremia in HIV- Infected and Uninfected Adults. *J Infect Dis* 2004; 189: 1996-2000.
31. Boivin G, Mackay I, Sloots TP, **Madhi S**, Freymuth F, Wolf D, Shemer-Avni Y, Ludewick H, Gray G, LeBlanc E. Global genetic diversity of the human Metapneumovirus fusion gene. *Emerg Infect Dis J* 2004; 10: 1154-1157.
32. Kristensen IA, Thiel S, Steffensen R, **Madhi S**, Sorour G, Olsen J. Mannan binding lectin (MBL) and RSV-lower respiratory tract infection leading to hospitalisation in children. A case-control study from Soweto, South Africa. *Scandanavian Journal of Immunology* 2004; 60: 184-188.
33. **Madhi SA**, Klugman KP and the Pneumococcal Vaccine Trialist Group. A role

- for *Streptococcus pneumoniae* in virus-associated pneumonia. *Nature Medicine*. 2004; 10, 811-813. (additional data on e-journal).
34. Martin M, Casellas J, **Madhi SA**, Urquhart T, Delport S, Ferrero F, Chamany S, Dayan G, Rose CE, Levine OS, Klugman KP, Feikin DR. Impact of *Haemophilus influenzae* Type b Conjugate Vaccine in South Africa and Argentina: Lessons for Estimating Impact in Low-Income Countries. *Pediatr Infect Dis J*. 2004; 23: 842-847.
 35. Klugman KP, **Madhi SA**. Oral antibiotics for the treatment of severe pneumonia in children. *Lancet* 2004; 364: 1104-1105.
 36. Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, Henderson FW, Cody Meissner H, **Madhi S**, Robertson D, Marshall H, Loh R, Sly P, Murphy B, Tatem JM, Randolph V, Hackell J, Gruber W, Tsai TF. Evaluation of Combined Live Attenuated Respiratory Syncytial Virus and Parainfluenza 3 Virus Vaccines in Infants and Young Children. *J Infect Dis*. 2004; 190: 2096-2103.
 37. **Madhi SA**, Heera JR, Kuwanda L, Klugman KP. Procalcitonin and C-reactive protein estimations improve the specificity of pneumococcal conjugate vaccine efficacy estimates against pneumonia. *PLoS Medicine*. 2005: e38.
 38. **Madhi SA**, Cutland C, Kuwanda L, Klugman KP. The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV infected and uninfected children. *Clin Infect Dis* 2005; 40:1511-1518
 39. **Madhi SA**, Kuwanda L, Cutland C, Holm A, Käyhty H, Klugman KP. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African HIV infected and uninfected children. *Ped Infect Dis J* 2005; 24: 410-416.
 40. Cherian T, Mulholland KE, Carlin JB, Ostensen H, Amin R, de Campo M, Greenberg D, Lagos R, Lucero M, **Madhi SA**, O'Brien KL, Obaro S, Steinhoff MC and the W.H.O. Radiology Working Group. Standardised Interpretation of Paediatric Chest Radiographs for the Diagnosis of Pneumonia in Epidemiological Studies. *Bulletin of WHO* 2005; 83: 353-359.
 41. Zar HJ, Jeena P, Argent A, Gie R, **Madhi SA**. Diagnosis and Management of Community Acquired Pneumonia in Childhood – South African Thoracic Society guidelines. *S Afr Med J* 2005; 95: 977-81, 984-90.
 42. Ludewick HP, Abed Y, van Niekerk N, Klugman KP, Boivin G and **Madhi SA**. Genetic variability of the human metapneumovirus in South Africa. *Emerg Infect Dis J*. 2005; 11: 1074-8.
 43. **Madhi SA**, Kuwanda L, Saarinen L, Cutland C, Mothupi R, Käyhty H, Klugman KP. Immunogenicity and effectiveness of *Haemophilus influenzae* type b conjugate vaccine in HIV infected and -uninfected African children. *Vaccine* 2005; 23: 5517-5525.
 44. **Madhi SA**, Kohler M, Kuwanda L; Cutland C; Klugman KP. Usefulness of C-reactive protein to define pneumococcal conjugate vaccine efficacy in the prevention of pneumonia. *Pediatr Infect Dis J* 2006; 25: 30-36.

45. Wright PF, Karron RA, **Madhi SA**, Treanor JJ, King JC, O'Shea A, Ikizler MR, Zhu Y, Collins PL, Cutland C, Randolph VB, Deatly A, Gruber WC, Murphy BR. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans *J.Infect Dis.*2006; 193:573-81.
46. Van Rie A, **Madhi SA**, Heera JR, Meddows-Taylor S, Wendelboe AM, Anthony F, Violari A, Tiemessen CT. Influence of intrauterine exposure to Human Immunodeficiency Virus on infant interferon gamma production to BCG and *Mycobacterium tuberculosis* antigens. *Clin Vaccine Immunol* .2006; 13:246-252.
47. **Madhi SA**, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, Murphy BR, Belshe RB, Karron RA, Deatly A, Gruber WC, Wright PF. Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. *Vaccine*. 2006; 24: 2432-2439.
48. **Madhi SA**, Ludewick H, Kuwanda L, van Niekerk N, Cutland C, Little T, Klugman KP. Pneumococcal co-infection with human metapneumovirus. *Journal of Infectious Diseases*. 2006; 193:1236-43.
49. **Madhi SA**, Kuwanda L, Cutland C, Klugman KP. Five-year cohort study of hospitalization for respiratory syncytial virus associated lower respiratory tract infection in African children. *J Clin Virology* 2006; 36: 215-21.
50. Levine OS, O'Brien KL, Knoll M, Adegbola RA, Black S, Cherian T, Dagan R, Goldblatt D, Grange A, Greenwood B, Hennessy T, Klugman K, **Madhi SA**, Mulholland K, Nohynek H, Santosham M, Saha SK, Scott AJ, Sow S, Whitney C, Cutts F. Pneumococcal vaccination in developing countries. *Lancet* 2006; 367: 1880-2.
51. von Gottberg A, de Gouveia L, **Madhi SA**, du Plessis M, Quan V, Soma K, Huebner R, Flannery B, Schuchat A, Klugman KP and the Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA) Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa. *Bulletin of WHO* 2006; 84:811-818.
52. Obaro S, **Madhi SA**. Pneumonia Vaccines and Childhood Pneumonia: Are we winning, refining or redefining? *Lancet Infect Dis* 2006; 6:150-161.
53. Zar H, **Madhi SA**. Childhood pneumonia- Progress and Challenges. *S. Afr Med J.*2006; 96:890-900.
54. **Madhi SA**, Adrian P, Kuwanda L, Jassat W, Jones S, Little T, Soininen A, Cutland C, Klugman KP. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. *Vaccine* 2007; 25: 2451-7.
55. **Madhi SA**, Klugman KP Sensitivity of "radiographically confirmed pneumonia" in measuring the burden of pneumococcal pneumonia prevented by conjugate pneumococcal vaccines: Is there space for improvement? *Vaccine* 2007; 25: 2413-9.
56. **Madhi SA**, Ludewick H, Kuwanda L, van Niekerk N, Cutland C, Klugman KP. Epidemiology of severe human metapneumovirus lower respiratory tract infection in an

- area with a high prevalence of human immunodeficiency virus type-1 infection. *Pediatr Infect Dis J*. 2007; 26: 693-9.
57. Siber GR, Chang I, Baker S, Fernsten P, Kate O'Brien K, Santosham M, Klugman KP, **Madhi SA**, Paradiso P, Kohberger R. Estimating the Protective Concentration of Anti-Pneumococcal Capsular Polysaccharide Antibodies. *Vaccine*. 2007; 25: 3 816-26.
 58. **Madhi SA**, Adrian P, Kuwanda L, Cutland C, Albrich WC, Klugman KP. Long-term effect of pneumococcal conjugate vaccine on nasopharyngeal colonization by *Streptococcus pneumoniae*--and associated interactions with *Staphylococcus aureus* and *Haemophilus influenzae* colonization--in HIV-Infected and HIV-uninfected children. *J Infect Dis*. 2007; 196: 1 662-6.
 59. Albrich WC, **Madhi SA**, Lafond KE, Klugman KP. Herd immunity after pneumococcal conjugate vaccination. *Lancet*. 2007; 370: 218-9.
 60. Klugman KP, **Madhi SA**, Feldman C. HIV and Pneumococcal Disease. *Curr Opin Infect Dis* 2007; 20: 11-15.
 61. Klugman KP, **Madhi SA**. Pneumococcal vaccines and flu preparedness. *Science* 2007; 316: 49-50.
 62. Cooper PA, **Madhi SA**, Huebner RE, Mbelle N, Abdool Karim SS, Kleinschmidt I, Forrest BD, Klugman KP. Apnea and its possible relationship to immunization in ex-premature infants. *Vaccine* 2008; 26: 3410-3.
 63. Edginton ME, Rakgokong L, Verver S, **Madhi SA**, Koornhof HJ, Wong ML, Hodgkinson HJ. Tuberculosis culture testing at a tertiary care hospital: options for improved management and use for treatment decisions. *Int J Tuberc Lung Dis*. 2008; 12: 786-91.
 64. Zar HJ, Madhi SA. Pneumococcal conjugate vaccine: A health priority. *S Afr Med J* 2008 June
 65. Green RJ, Feldman C, Schoub B, Richards GA, **Madhi SA**, Zar HJ, Lalloo U. Influenza guideline for South Africa- update 2008. *S Afr Med J* 2008; 98: 224-30.
 66. **Madhi SA**, Levine OS; Hajjeh R, Mansoor OD, Cherian T. Vaccines to prevent pneumonia and improve child survival. *Bulletin of WHO* 2008; 86: 365-372 .
 67. **Madhi SA**, Whitney C, Nohynek H. Lessons learned from Clinical Trials Evaluating Pneumococcal Conjugate Vaccine Efficacy against Pneumonia and Invasive Disease. *Vaccine*, 2008; 26, (Suppl 2), B9-B15.
 68. Klugman KP, **Madhi SA**, Albrich W. Novel approaches to the diagnosis of *Streptococcus pneumoniae* as a cause of community acquired pneumonia. *Clin Infect Dis*. 2008; 47 (Suppl 3) S202-6.
 69. **Madhi SA**, Schoub B, Klugman KP. Interaction between influenza virus and *Streptococcus pneumoniae* in the aetiology of severe pneumonia. *Expert Review of Respiratory Medicine* 2008; 2; 663-672.
 70. Zar H, **Madhi SA**. Pneumococcal conjugate vaccine- advancing child health in South Africa. *South African Journal of Child Health*. 2008; 2: 94-95.

71. du Plessis M, von Gottberg A, Madhi SA, Hattingh O, de Gouveia L, Klugman KP for the Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa (GERMS-SA). Prevalence of serotype 6C among invasive pneumococcal isolates previously identified as serotype 6A in South Africa. *Int J Antimicrob Agents* 2008 ; 32S; S66–S70.
72. Violari A, Cotton M, Gibb D, Babiker A, Steyn J, **Madhi SA**, Jean-Philippe P and McIntyre J on behalf of the CHER Study Team. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Trial. *New Eng J Med* 2008; 359:2233-44.
73. Neto HB, Farhat CK, Tregnaghi MW, **Madhi SA**, Razmpour A, Palladino G, Small MG, Gruber WC, Forrest B on behalf of the D153-P504 LAIV Study Group. Efficacy and Safety of One and Two Doses of LAIV in Vaccine-Naive Children. *Pediat Infect Dis J*. 2009; 28: 365-71.
74. **Madhi SA**, Kuwanda L, Cutland C, Käyhty H, Klugman KP; Adrian P. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and -uninfected children 5 years post-vaccination. *J Infect Dis*. 2009; 199: 1168- 76.
75. Klugman KP, Chien YW, **Madhi SA**. Pneumococcal pneumonia and influenza: a deadly combination. *Vaccine* 2009; 27 Suppl 3. C9-C14
76. Steele D, Cunliffe N, Tumbo J, **Madhi SA**, De Vos B, Bouckennooghe A. Rotavirus Infection and Immunization in HIV-infected Children: A review. *J Infect Dis* 2009; 200 Suppl 1, S57-S62.
77. Cutland CL, **Madhi SA**, Zell ER, Kuwanda L, Laque M, Groome M, Gorwitz R, Thigpen M, Patel R, Velaphi SC, Adrian P, Klugman KP, Schuchat A, Schrag S and the PoPS trial team* A phase III placebo-controlled, randomised trial evaluating the efficacy of chlorhexidine maternal-vaginal and neonate body wipes in reducing neonatal sepsis and vertical transmission of pathogenic bacteria in South Africa. *Lancet* 2009; 374:1909-1916.
78. Nohynek H, **Madhi SA**, Grijalva CG. Childhood bacterial respiratory diseases. *Pediatr Infectious Dis J*. 2009; 28: S127-S132.
79. Koornhof HF, Madhi SA, Feldman C, von Gottberg A, Klugman KP. A Century of South African Battles against Pneumococcus -The Captain of Death. *Southern African J Epi and Infect* 2009, 24: 7-19.
80. Mothibeli KM, du Plessis M, von Gottberg A, de Gouveia L, Adrian P, **Madhi SA**, Klugman KP for GERMS-SA (Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa). An unusual pneumococcal sequence type is the predominant cause of serotype 3 invasive disease in South Africa. *J Clin Microbiology*. 2010. 48:184-91.
81. Poolman JT, Frascch CE, Kayhty H, Lestrade P, **Madhi SA**, Henckaerts I. Evaluation of

- pneumococcal polysaccharide immunoassays using 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines. *Clin Vaccine Immunol.* 2010. 17: 134-42.
82. Mangtani P, Mulholland K, **Madhi SA**, Edmond K, O'Loughlin R, Hajjeh R. *Haemophilus influenzae* type b disease in HIV-infected children: A review of the disease epidemiology and effectiveness of Hib conjugate vaccines. *Vaccine* 2010. 28: 1677-83.
 83. **Madhi SA**, Cunliffe NA, Duncan SA, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Chevart BB, Han HH, Neuzil KM. Impact of Human Rotavirus Vaccine on Severe Gastroenteritis in African Infants. *New Eng J Medicine.* 2010. 362: 289-98.
 84. Theodoratou E, Johnson S, Jhass A, **Madhi SA**, Clark A, Boschi-Pinto C, Bhopal S, Rudan I, Campbell H. The effect of *Haemophilus influenzae* type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality. *International Journal of Epidemiology.* 2010. 39: i172:i185.
 85. Nair H, Nokes JD, Gessner BD, Dherani M, **Madhi SA**, Singleton RJ, O'Brien KL, RocaA, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, NgamaM, Munywoki PK, Rudan I, Weber MW, Campbell H. Global Burden of Acute Lower Respiratory Infections due to Respiratory Syncytial Virus in Young Children. *Lancet.* 2010; 375: 1455-1465.
 86. Hartley C; Pretorius K; Mohamed A; Laughton B; **Madhi SA**; Cotton MF; Steyn, B; Seedat S. Maternal postpartum depression and infant social withdrawal among human immunodeficiency virus (HIV) positive mother-infant dyads. *Psychol Health Med.* 2010; 15: 278-87.
 87. Green RJ; Zar HJ; Jeena PM; **Madhi SA**; Lewis H. South African guideline for the diagnosis, management and prevention of acute viral bronchiolitis in children. *S Afr Med J*; 2010; 100: 322-5.
 88. **Madhi SA**; Adrian P; Cotton MF; McIntyre JA; Jean-Philippe P; Meadows S; Nachman S; Kayhty H; Klugman KP; Violari A. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. *J Infect Dis*; 2010: 202; 355: 61.
 89. Moore D, Klugman KP, **Madhi SA**. Role of *Streptococcus pneumoniae* in hospitalization for acute community-acquired pneumonia associated with culture-confirmed *Mycobacterium tuberculosis* in children: A Pneumococcal Conjugate Vaccine Probe Study. *Pediatr Infect Dis J*; 2010: 29(12):1099-04.
 90. Cohen C, Simonsen L, Kang JW, Miller M, McAnerney J, Blumberg L, Schoub B, **Madhi SA**, Viboud C. Influenza-related excess mortality in South African seniors, 1998-2005. *Clin Infect Dis*; 2010: Dec 15;51(12):1362-9.
 91. Kruczek A, Cutland C, **Madhi SA**. Review of the effect of maternal HIV infection on measles-susceptibility during early infancy: Implications for optimizing protection of the infant. *HIV Therapy.* 2010: 4; 471-482.

92. Steele AD, **Madhi SA**, Louw CE, Bo P, Tumbo JT, Werner CM, De Vos B, Bicer C, Delem A, Han HH. Safety, reactogenicity and immunogenicity of human rotavirus vaccine RIX4414 in HIV-positive infants in South Africa. *Pediatr Infect Dis J*; 2011 Feb;30(2):125-30.
93. **Madhi SA**, Maskew M, Koen A, Kuwanda L, Besselaar TG, Naidoo D, Cohen C; Cutland C, Sanne I. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomised clinical trial of efficacy, immunogenicity and safety. *Clin Infect Dis*; 2011 Jan 1;52(1):128-37
94. Roupheal N, Steyn S, Bangert M, Sampson JS, Adrian P, **Madhi SA**, Klugman KP, Ades AW. Use of Two Pneumococcal Common Protein real-time PCR assays in healthy children colonized with *Streptococcus pneumoniae*. *Diag Microb Infect Dis*; 2011; 70: 215-9.
95. Fairlie L, Beylis NC, Reubenson G, Moore DP, **Madhi SA**. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. *BMC Infect Dis*. 2011. 11:28.
96. **Madhi SA**, Cutland C, Jones S, Groome M, Ortiz E. Immunogenicity and safety of an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Hib-conjugate combined vaccine (Pentaxim) and monovalent hepatitis B vaccine at 6, 10 and 14 weeks of age in infants in South Africa. *S Afr Med J*. 2011 Feb;101(2):126-31.
97. Webster J, Theodoratou E, Nair H, Seong AC, Zgaga L, Huda T, Johnson HL, **Madhi S**, Rubens C, Zhang JS, El Arifeen S, Krause R, Jacobs TA, Brooks AW, Campbell H, Rudan I. An evaluation of emerging vaccines for childhood pneumococcal pneumonia. *BMC Public Health*. 2011 Apr 13;11 Suppl 3:S26.
98. Madzivhandila M, Adrian PV, Cutland CL, Kuwanda L, Schrag SJ, **Madhi SA**. Serotype distribution and invasive potential of group B streptococcus isolates causing disease in infants and colonizing maternal-newborn dyads. *PLoS One*. 2011 Mar 21;6(3):e17861.
99. **Madhi SA**, Mitha I, Cutland C, Groome M, Santos-Lima E. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. *Pediatr Infect Dis J*. 2011 Apr;30(4):e68-74.
100. Nunes MC, von Gottberg A, de Gouveia L, Cohen C, Moore DP, Klugman KP, **Madhi SA**. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. *AIDS*. 2011 Feb 20;25(4):453-62.
101. Kasambira TS, Shah M, Adrian PV, Holshouser M, **Madhi SA**, Chaisson RE, Martinson NA, Dorman SE. QuantiFERON®-TB Gold In-Tube for the detection of *Mycobacterium tuberculosis* infection in children with household tuberculosis contact. *Int J Tuberc Lung Dis*; 2011; 15(5):628–634

102. **Madhi SA**, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, Jean-Philippe P, McSherry G, Mitchell C; P1041 Study Team. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. *N Engl J Med*. 2011 Jul 7;365(1):21-31.
103. Klugman KP, **Madhi SA**, Adegbola RA, Cutts F, Greenwood B, Hausdorff WP. Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose. *Vaccine* 29 (2011) 3372–3373
104. Rees H, **Madhi SA**. Will the Decade of Vaccines mean business unusual? *Lancet*; 2011; 378: 382-5.
105. Visser A, Moore DP, Whitelaw A, Lowman W, Kantor G, Hoosen A, **Madhi SA**, Brink A, van den Bergh D, Devenish L, Moodley P, Apalata T, Duse AG, Gelband H. Part VII. Antibiotic Resistance Interventions: Part VII. *S. Afr Med J*. 2011; 101 (8): 587-95.
106. Nunes M, **Madhi SA**. Review on the safety and immunogenicity of PCV-13 in infants and toddlers. *Exp Rev Vaccines*, 2011; 10; 951-979.
107. Plotkin S, Liese J, **Madhi SA**, Oritz E. A DTaP-IPV/PRP-T vaccine (Pentaxim™): A review of 16 years of clinical experience. *Exp Rev Vaccines*, 2011; 10; 975-999.
108. Hainline C, Taliep R, Sorour G, Nachman S, Rabie H, Dobbels E, Janse van Rensburg A, Cornell C, Violari A, **Madhi SA** and Cotton MF. Early antiretroviral therapy reduces the incidence of otorrhea in a randomized study of early and deferred antiretroviral therapy: Evidence from the Children with HIV Early Antiretroviral Therapy (CHER). *BMC Research Notes*; MS : 1985179335553860
109. Punpanich W; Groome M; Muhe L; Qazi SA; **Madhi SA**. Systematic review on the etiology and antibiotic treatment of pneumonia in HIV-infected children. *Pediatr Infect Dis J*; 2011; 30 (10): e192-202.
110. Nair H, Brooks AW, Katz M, Roca A, Berkley JA, **Madhi SA**, Simmerman JM, Gordon A, Sato M, Howie S, Krishnan A, Ope M, Lindblade KA, Carosone-Link P, Lucero M, Ochieng W, Kamimoto L, Dueger E, Bhat N, Vong S, Theodoratou E, Chittaganpitch M, Chimah O, Balmaseda A, Buchy P, Harris E, Evans V, Katayose M, Gaur B, O'Callaghan-Gordo C, Goswami D, Arvelo W, Venter M, Briese T, Tokarz R, Widdowson M A, Mounts AW, Breiman RF, Feikin DR, Klugman KP, Olsen SJ, Gessner BD, Wright PF, Rudan I, Broor S, Simoes EA, Campbell H. The global burden of respiratory infections due to seasonal influenza in 2 young children: a systematic review and meta-analysis. *Lancet*; 2011; 378: 1917-30.
111. Rabie H, Violari A, Duong T, **Madhi SA**, Josipovic D, Innes S, Dobbels E, Lazarus E, Panchia R, Babiker AG, Gibb DM, Cotton MF for the CHER team. Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis. *Int J Tuberc Lung Dis*; 2011 15(9):1–7.
112. **Madhi SA**, Violari A, Klugman KP, Lin G, McIntyre JA, Gottberg AV, Jean-Philippe P, Cotton MF, Adrian P on behalf of the CIPRA 4 team. Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal

- colonization by *Streptococcus pneumoniae* during the primary series of immunization. *Vaccine*; 2011. 29 (40) :6994-7001.
113. Shah M, Kasambira TS, Adrian PV, **Madhi SA**, Martinson NA, Dorman SE. Longitudinal Analysis of QuantiFERON-TB Gold In-Tube in Children with Adult Household Tuberculosis Contact in South Africa: A Prospective Cohort Study. *PLoS One*; 2011; 6: e26787.
 114. Nunes M, von Gottberg A, de Gouveia L, Cohen C, Kuwanda L, Karstaedt A S, Klugman KP, Madhi SA. Persistent high burden of invasive pneumococcal disease in South African HIV-infected adults in the era of an antiretroviral treatment program. *PlosOne*; 2011: 11: e27929
 115. Groome M, **Madhi SA**. Five-year Cohort Study on the Burden of Hospitalisation for Acute Diarrhoeal Disease in African HIV-infected and HIV-uninfected Children: Potential Benefits of Rotavirus Vaccine. *Vaccine* . 2012; 30(Suppl1): A173-8.
 116. **Madhi SA**, Kirsten M, Louw C, Bos P, Aspinall S, Bouckenoghe A, Neuzil KM, Steele AD. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. *Vaccine*. 2012; 30(Suppl1): A44-51.
 117. Nunes MC, **Madhi SA**. Review: Safety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals. *Human Vacc Immuno*. 2012 ; 8(2): 161-73.
 118. **Madhi SA**, Cutland C, Jones S, Groome M, Ortiz E. One-year post-primary antibody persistence and booster immune response to a DTaP-IPV//PRP~T Vaccine (Pentaxim[®]) given at 18-19 months of age in South African children primed at 6, 10 & 14 weeks of age with the same vaccine. *S Afr Med J*. 2011; 101: 879-883.
 119. Groome MJ, Albrich WC, Wadula J, Khoosal M, **Madhi SA**. Community-onset *Staphylococcus aureus* bacteraemia in hospitalised African children: high incidence in HIV-infected children and high prevalence of multidrug resistance. *Pediatr Int Child Health*. 2012; 32(3): 140-6.
 120. Son M, Weiser J, Shchepetov M, Adrian P, **Madhi SA**, de Gouveia L, von Gottberg A, Klugman K and Dawid S. Conserved Mutations in the Pneumococcal Bacteriocin Transporter Gene, blpA, Results in a Complex Population Consisting of Producers and Cheaters. *mBio* 2011; 2(5): e00179-11.

121. Wiysonge CS, Armah GE, **Madhi SA**, Were F, Kitaka SB, Akoua-Koffi C, et al. The African Vaccine-Preventable Diseases Network: a vaccine advocacy initiative. *Pan Afr Med J*; 2011; 8: 24.
122. Jaspan HB, Myer L, **Madhi SA**, Violari A, Gibb G, Stevens WS, Dobbels E, and Cotton MF. Utility of clinical parameters to identify HIV infection in infants below ten weeks of age in South Africa: a prospective cohort study. *BMC Pediatrics*. 2011; 11:104.
123. Nzenze S, Klugman KP, **Madhi SA**. The potential impact of the 13-valent conjugate pneumococcal vaccine on antibiotic resistance in pneumococci. *South Afr J Epidemiol Infect* 2011;26(4)(Part II):253-258.
124. Schrag S, Baker C, Beall B, Boslego J, Carlone G, Klugman KP, **Madhi SA**, McGee L, Messonnier N, Neuzil K, Schuchat A, Romero-Steiner S, Verani J, Whitney C, Zaidi A (2011). Group B streptococcal vaccine for resource-poor countries. *Lancet*, 2011; 378 pp. 11 - 12.
125. Visser A, Moore DP, Whitelaw A, Lowman W, Kantor G, Hoosen A, **Madhi SA**, Brink A, van den Bergh D, Devenish L, Moodley P, Apalata T, Duse AG, Gelband H. Part V: Interventions against antimicrobial resistance. *S. Afr Med J*; 2011: 101 (8 Pt2): 587-95.
126. Albrich WC, **Madhi SA**, Adrian PV, van Niekerk N, Mareletsi T, Cutland C, Wong M, Khoosal M, Karstaedt A, Zhao P, Deatly A, Sidhu M, Jansen KU, Klugman KP. Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumonia. *Clin Infect Dis*, 2012; 54:601-9.
127. von Gottberg A, Cohen C, Whitelaw A, Chhagan M, Flannery B, Cohen AL, de Gouveia L, du Plessis M, **Madhi SA**, Klugman KP. Invasive disease due to *Haemophilus influenzae* type b ten years after routine vaccination in South Africa, 2003-2009. *Vaccine*; 2012; 30: 565-71.
128. Robertson A, Firth GB, Truda C, Ramdass DA, Groome MJ, **Madhi SA**. Epidemiology of acute osteo-articular sepsis in a setting with a high prevalence of pediatric HIV infection. *J Pediatr Ortho*; 2012; 32 (2):215-9.
129. Reed C, **Madhi SA**, Klugman KP, Kuwanda L, Ortiz JR, Finelli L, Fry AM. Development of the Respiratory Index of Severity in Children (RISC) score among young children with respiratory infections in South Africa. *PlosOne*. 2012; 7: e27793.
130. Omer SB, Bednarczyk R, **Madhi SA**, Klugman KP. Benefits to mother and child of influenza vaccination during pregnancy. *Hum Vaccin Immunother*. 2012; 8(1):130-7.
131. Hesseling AC, Kim S, **Madhi SA**, Nachman S, Schaaf HS, Violari A, Victor TC, McSherry G, Mitchell C, Cotton MF for the IMPAACT P1041 Team. High prevalence of drug resistance among HIV-exposed and infected children on a tuberculosis prevention trial. *Int J Tuberc Lung Dis*. 2012; 16 (2):192-5.
132. Dagnev AF, Cunningham MC, Dube Q, Edwards MS, French N, Heyderman RS, **Madhi SA**, Slobod K, Clemens SUA. Understanding variation in neonatal Group B Streptococcal disease incidence in developing countries. *Clin Infect Dis*. 2012; 55: 91-102.

133. Graham SM, Ahmed T, Amanullah F, Browning R, Cardenas V, Casenghi M, Cuevas LE, Gale M, Gie RP, Grzemska M, Handelsman E, Hatherill M, Hesselning AC, Jean-Philippe P, Kampmann B, Kabra SK, Lienhardt C, Lighter-Fisher J, **Madhi SA**, Makhene M, Marais BJ, McNeeley DF, Menzies H, Mitchell C, Modi S, Mofenson L, Musoke P, Nachman S, Powell C, Rigaud M, Rouzier V, Starke JR, Swaminathan S, Wingfield C. Evaluation of TB diagnostics in children: Proposed clinical case definitions for classification of intra-thoracic tuberculosis disease. Consensus from an Expert Panel. *J Infect Dis.* 2012; 205 (Supp2); S199-208.
134. Levine OS, O'Brien KL, Deloria-Knoll M, Murdoch DR, Feikin DR, Deluca AN, Driscoll AJ, Baggett HC, Brooks WA, Howie SR, Kotloff KL, **Madhi SA**, Maloney SA, Sow S, Thea DM, Scott JA. The pneumonia etiology research for child health project: a 21st century childhood pneumonia etiology study. *Clin Infect Dis.* 2012 ;54 Suppl 2:S93-S101.
135. Schrag SJ, Cutland CL, Zell ER, Kuwanda L, Buchmann E, Velaphi SC, Groome MJ, **Madhi SA**. Risk factors for neonatal sepsis and perinatal death among infants enrolled in the Prevention of Perinatal Sepsis Trial, Soweto, South Africa. *Pediatr Infect Dis J*; 2012, 2012, 31 (8): 821-6.
136. Punpanich W; Groome M; Muhe L; Qazi SA; **Madhi SA**. Antibiotic and systemic therapies for pneumonia in Human Immunodeficiency Virus (HIV)-infected and HIV-exposed children: A systematic review. *J Infect Dev Countries*; 2012; 6 (2): 109-19.
137. Sinha A, Kim S, Ginsberg G, Franklin H, Kohberger R, Strutton D, **Madhi SA**, Griffiths UK, Klugman KP. Economic burden of acute lower respiratory tract infection in South African children. *Paediatr Int Child Health.* 2012; 32 (2): 65-73.
138. Kiser JJ, Zhu R, D'Argenio DZ, Cotton M, Bobat R, McSherry G, **Madhi S**, Carey V, Seifart H, Werely C, Fletcher CV. Isoniazid pharmacokinetics and dosing in South African infants. *Therapeutic Drug Monitoring* 2012; 36 (4): 446-451.
139. Loughton B, Cornell M, Grove D, Kidd M, Springer PE, Dobbels E, Janse van Rensburg A, Violari A, Babiker AG, **Madhi SA**, Jean-Phillipe P, Gibb DM, Cotton MF. Early antiretroviral therapy improves neurodevelopmental outcomes in infants. *AIDS*; 2012; 26 (13): 1685-1690.
140. **Madhi SA**, Cohen C, von Gottberg A. Introduction of pneumococcal conjugate vaccine into the public immunization program in South Africa: translating research into policy. *Vaccine.* 2012, 30(Suppl3): C21-7.
141. Wiysonge SC, Ngcobo NJ, Prakash JM, **Madhi SA**, Schoub BD, Hawkridge A, Shey MS, Hussey GD. Advances in childhood immunisation in South Africa: where to now? Programme managers views and evidence from systematic reviews. *BMC Public Health.* 2012. 12: 578 (MS: 2002286525661538)
142. Cutland CL, Schrag SJ, Zell ER, Kuwanda L, Buchmann E, Velaphi SC, Groome MJ, Adrian PV, **Madhi SA**. Maternal HIV infection and vertical transmission of pathogenic bacteria. *Pediatrics*; 2012; 130 (3): 1-10.

143. Tokarz R, Firth C, **Madhi SA**, Howie SR, Wu WY, Sall AA, Haq S, Briese T, Lipkin WI. Worldwide emergence of multiple clades of enterovirus 68. *J Gen Virol.* 2012; 93 (9): 1952-8.
144. Steele AD, Neuzil KM, Cunliffe NA, **Madhi SA**, Bos P, Ngwira B, Witte D, Todd S, Louw C, Kirsten M, Aspinall S, Jan van Doorn L, Bouckenoghe L, Suryakiran PV, Han HH. Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. *BMC Infect Dis* 2012; 12: 213 (e1296340893655593).
145. Cohen C, Simonsen L, Sample J, Kang JW, Miller M, **Madhi SA**, Campsmith M, Viboud C. Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America. *Clin Infect Dis* 2012. 55(7): 996-1003.
146. Venter M, Naidoo D, Pretorius M, Treurnicht F, Buys A, McAnerney J, Blumberg L, **Madhi SA**, Cohen C, Schoub B. Evolutionary dynamics of Pandemic H1N1/09 in South Africa from 2009-2010. *J Infect Dis* 2012; 206 (suppl1): S166-S172.
147. Pretorius MA, **Madhi SA**, Cohen C, Naidoo D, Groome M, Moyes J, Buys A, Walaza S, Dawood H, Chhagan M, Haffjee S, Kahn K, Puren A, Venter M. Prevalence of respiratory viral co-infections in South Africans hospitalized for Severe Acute Respiratory Illness during 2009 and 2010. *J Infect Dis* 2012. 206 (Suppl1): S59-65.
148. Moore D, Dagan R, **Madhi SA**. Respiratory viral and pneumococcal co-infection of the respiratory tract: implications of pneumococcal vaccination. *Exp Rev Resp Med.* 2012. 6(4): 451-65.
149. **Madhi SA**, Wals PD, Grijalva CG, Grimwood K, Grossman R, Ishiwada N, Lee PI, Nascimento-Carvalho C, Nohynek H, O'Brien KL, Vergison A, Wolter J. The Burden of Childhood Pneumonia in the Developed World: A Review of the Literature. *Pediatr Infect Dis J*; 2013; 32 (3); e119-e127.
150. **Madhi SA**, Dittmer S, Kuwanda L, Venter M, Cassim H, Lazarus E, Thomas T, Liberty A, Treurnich F, Cutland CL, Weinberg A, Violari A. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial. *AIDS.* 2013; 27(3): 369-79.
151. Nunes MC, **Madhi SA**. Review of a new fully liquid, hexavalent vaccine: Hexaxim. *Exp Opinion Bio Therapy.* 2013; 13 (4): 575-93.
152. Nair H, Simoes EA, Rudan I, Gessner BD, Azziz-Baumgartner E, Zhang JS, Feikin DR, Mackenzie GA, Moisi JC, Roca A, Baggett HC, Zaman SM, Singleton RJ, Lucero MG, Chandran A, Gentile A, Cohen C, Krishnan A, Bhutta ZA, Arguedas A, Clara AW, Andrade AL, Ope M, Ruvinsky RO, Hortal M, McCracken JP, **Madhi SA**, Bruce N, Qazi SA, Morris SS, El Arifeen S, Weber MW, Scott JA, Brooks WA, Breiman RF, Campbell H. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. *Lancet.* 2013: 381(9875): 1380-90. .

153. Madzivhandila M, Adrian PV, Cutland CL, Kuwanda L, **Madhi SA**. Distribution of pilus islands of group B streptococcus associated with maternal colonization and invasive disease in South Africa. *J Med Microbiol*. 2013; 62 (2): 249-53.
154. Boyles TH, Bamford C, Bateman K, Blumberg L, Dramowski A, Karstaedt A, Korsman S, le Roux DM, Maartens G, **Madhi SA**, Naidoo R, Nuttall J, Reubenson G, Taljaard J, Thomas J, van Zyl G, von Gottberg A, Whitelaw A, Mendelson M. Guidelines for the management of acute meningitis in children and adults in South Africa. *South Afr J Epidemiol Infect*. 2013;28(1):5-15.
155. **Madhi SA**, Koen A, Cutland C, Groome M, Santos-Lima E. Antibody Persistence and Booster Vaccination of a Fully Liquid Hexavalent Vaccine Co-Administered with Measles/Mumps/Rubella and Varicella Vaccines at 15-18 Months of Age in Healthy South African Infants. *Pediatr Infect Dis J*; 2013; 32(8): 889-97.
156. **Madhi SA**, Izu A, Violari A, Cotton MF, Panchia R, Dobbels E, Sewraj P, van Niekerk N, Jean-Philippe P, Adrian PV. Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants. *Vaccine*. 2013; 31(5): 777-83.
157. von Gottberg A, Cohen C, de Gouveia L, Meiring S, Quan V, Whitelaw A, Crowther-Gibson P, **Madhi SA**, Whitney CG, Klugman KP. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008. *Vaccine*. 2013; 31 (38): 4200-8.
158. Simani OE, Adrian PV, Violari A, Kuwanda L, Ot wombe K, Nunes MC, Cotton MF, **Madhi SA**. Effect of in-utero HIV exposure and antiretroviral treatment strategies on measles susceptibility and immunogenicity of measles vaccine. *AIDS*. 2013; 27(10):1583-91.
159. Dangor Z, Izu A, Hillier K, Solomon F, Beylis N, Moore DP, Nunes MC, **Madhi SA**. Impact of the Antiretroviral Treatment Program on the Burden of Hospitalization for Culture-Confirmed Tuberculosis in South African Children: A Time-Series Analysis. *Pediatr Infect Dis J*. 2013. 32(9): 972-7.
160. Nunes MC, Shiri T, van Niekerk N, Cutland CL, Groome MJ, Koen A, von Gottberg A, de Gouveia L, Klugman KP, Adrian PV, **Madhi SA**. Acquisition of *Streptococcus pneumoniae* in Pneumococcal Conjugate Vaccine-Naive South African Children and Their Mothers. *Pediatr Infect Dis J*. 2013; 32(5): e192-e205.
161. Kwatra G, **Madhi SA**, Cutland C, Buchmann E, Adrian PV. Evaluation of Trans-Vag broth, CNA agar and CHROMagar StrepB for the detection of Group B Streptococcus in vaginal and rectal swabs from pregnant women in South Africa. *J Clin Microb*. 2013. 51(8): 2515-9.
162. **Madhi SA**, Dangor B, Heath PT, Schrag S, Izu A, Sobanjo-ter Meulen A, Dull PM. Considerations for a Phase-III trial to evaluate a Group B Streptococcus polysaccharide-protein conjugate vaccine in pregnant women for the prevention of

- early- and late-onset invasive disease in young-infants. 2013. *Vaccine*. 31 (Suppl 4): D52-7.
163. Ditse Z, Adrian PV, Kuwanda L, **Madhi SA**. Association of *Streptococcus pneumoniae* common protein antibodies and pneumococcal nasopharyngeal colonization in HIV-infected and HIV-uninfected African children. *Vaccine*. 2013. 31(40): 4421-7.
 164. Cohen C, Moyes J, Tempia S, Groome M, Walaza S, Pretorius M, Dawood H, Chagan M, Haffejee S, Variava E, Kahn K, Tshangela A, von Gottberg A, Wolter N, Cohen AL, Kgekong B, Venter M, **Madhi SA**. Severe influenza-associated lower respiratory tract infection in a high HIV-prevalence setting-South Africa, 2009-2011. *Emerg Infect Dis* 2013, 19(11): 1766-74.
 165. Nzenze SA, Shiri T, Nunes M.C, Klugman K.P, Kahn K, Twine R, de Gouveia L, von Gottberg A, **Madhi S.A**. Temporal changes in pneumococcal colonization in a rural-African community with high HIV-prevalence following routine infant pneumococcal-immunization. *Pediatr Infect Dis J*. 2013; 32(11): 1270-8.
 166. Jones SA, Groome M, Koen A, van Niekerk N, Sewraj P, Mabunda X, Kuwanda L, Izu A, Adrian PV, **Madhi SA**. Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants. *PlosOne* 2013. 8(8): e72794.
 167. Msimang VM, Page N, Groome MJ, Moyes J, Cortese M, Seheri M, Kahn K, Chagan M, **Madhi SA**, Cohen C. *Pediatr Infect Dis J*. 2013. 32(12): 1359-64.
 168. Moyes J, Cohen C, Pretorius M, Groome M, von Gottberg A, Wolter N, Walaza S, Haffejee S, Chhagan M, Naby F, Cohen AL, Tempia S, Kahn K, Dawood H, Venter M, **Madhi SA**. Epidemiology of respiratory syncytial virus-associated acute lower respiratory tract infection hospitalizations among HIV-infected and HIV-uninfected South African children, 2010-2011. *J Infect Dis*. 2013. 2088 (Suppl 3): S217-26.
 169. Pretorius MA, van Niekerk S; Tempia S; Cohen C, **Madhi SA**, Venter M. Replacement and positive evolution of subtype A and B Respiratory Syncytial Virus G-protein genotypes from 1997-2012 in South Africa. *J Infect Dis*. 2013. 208(Suppl3): S227-37.
 170. Zar HJ, **Madhi SA**, Aston SJ, Gordon SB. Pneumonia in low and middle income countries: progress and challenges. *Thorax*. 2013; 68(11): 1052-6.
 171. Nascimento-Carvalho CM, **Madhi SA**, O'Brien KL. Review of Guidelines for Evidence-based Management for Childhood Community-acquired Pneumonia from between Developed and Developing Countries. *Pediatr Infect Dis J*. 2013. 32(11): 1281-2.
 172. Shiri T, Auranen K, Nunes MC, Adrian PV, van Niekerk N, de Gouveia L, von Gottberg A, Klugman KP, **Madhi SA**. Dynamics of pneumococcal transmission in vaccine-naïve children and their HIV-infected or HIV-uninfected mothers during the first two years of life" with the following category. *Am J Epidemiol*. 2013. 178(11):1629-37.

173. Cotton MF, Violari A, Otjombe K, Panchia R, Dobbels E, Rabie H, Josipovic D, Liberty A, Lazarus E, Innes S, van Rensburg AJ, Pelsler W, Truter H, **Madhi SA**, Handelsman E, Jean-Philippe P, McIntyre JA, Gibb DM, Babiker AG. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. *Lancet*. 2013. 382(9904): 1555-63.
174. Shiri T, Nunes MC, Adrian PV, Van Niekerk N, Klugman KP, **Madhi SA**. Interrelationship of *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Staphylococcus aureus* colonization within and between pneumococcal-vaccine naive mother-child dyads. *BMC Infect Dis*. 2013; 13(1):483.
175. Kayhty H, Auranen K, Dagan R, Goldblatt D, O'Brien K, Scott A, Antonio M, Lucero M, **Madhi SA**, Klugman KP, Mulholland K. Case for carriage. *Vaccine* 2013; 32(1): 180-203.
176. Chevart B, Neuzil KM, Steele D.A, Cunliffe N, **Madhi SA**, Karkada N, Han H.H., Vinals C. Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: analysis of clinical trials of human rotavirus vaccine. *Hum Vacc Immunol*. 2014. 10(2): 505-11.
177. Wolter N, Cohen C, Tempia S, **Madhi SA**, Venter M, Moyes J, Walaza S, Malope Kgokong B, Groome M, du Plessis M, Pretorius M, Dawood H, Kahn K, Variava E, Klugman KP, von Gottberg A. HIV and Influenza Virus Infections Are Associated With Increased Blood Pneumococcal Load: A Prospective, Hospital-Based Observational Study in South Africa, 2009-2011. *J Infect Dis*; 2014; 1: 56-65.
178. **Madhi SA**, Kuwanda L, Venter M, Violari A. Prospective Cohort Study Comparing Seasonal and H1N1(2009) Pandemic Influenza Virus Illnesses in HIV-infected Children During 2009. *Pediatr Infect Dis J*. 2014; 33(2): 174-6.
179. Nunes MC, Kushner Z, Radebe Z, Madimabe R, van Niekerk N, Moloi J, Kuwanda L, Rossen JW, Klugman KP, Adrian PV, **Madhi SA**. Clinical epidemiology of bocavirus, rhinovirus, two polyomaviruses and four coronaviruses in HIV-infected and HIV-uninfected South African children. *PlosOne*. 2014; 9 (2): e86448.
180. Simani OE, Izu A, Violari A, Cotton MF, van Niekerk N, Adrian PV, **Madhi SA**. Effect of HIV-1 exposure and antiretroviral treatment strategies in HIV-infected children on immunogenicity of vaccines during infancy. *AIDS*. 2014; 28 (4): 531-41.
181. **Madhi SA**, Kuwanda L, Venter M, Violari A. Prospective cohort study comparing incidence of seasonal and H1N1(2009)-pandemic influenza virus illness in HIV-infected children during 2009. *Pediatr Infect Dis J*. 2014; 33(2): 174-6.
182. Dangor Z, Izu A, Moore DP, Nunes MC, Solomon F, Beylis N, von Gottberg A, McAnerney JM, **Madhi SA**. Temporal association in hospitalizations for tuberculosis, invasive pneumococcal disease and influenza virus illness in South African children. *PLoS One*. 2014; 9(3): e91464.

183. Kim SY, Russell LB, Park J, Verani JR, **Madhi SA**, Cutland CL, Schrag SJ, Sinha A. Cost-effectiveness of a potential group B streptococcal vaccine program for pregnant women in South Africa. *Vaccine* 2014. 1954-1963.
184. Groome MJ, Moon S-S, Velasquez D, Jones S., Koen A, van Niekerk N, Jaing B, Parashar ID, **Madhi SA**. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa. *Bull World Health Org.* 2014. 92 (4): 238-45.
185. Tempia S, Walaza S, Viboud C, Cohen AL, **Madhi SA**, Venter M, McAnerney J, Cohen C. Mortality Associated with Seasonal and Pandemic Influenza and Respiratory Syncytial Virus among Children less than 5 Years of Age in a High HIV-Prevalence Setting - South Africa, 1998-2009. *Clin Infect Dis.* 2014. 58 (9): 1241-9.
186. Cohen AL, Hellferscee O, Pretorius M, Treurnicht F, Walaza S, **Madhi SA**, Groome M, Dawood H, Variava E, Kahn K, Wolter N, von Gottberg A, Tempia S, Venter M, Cohen C. Epidemiology of influenza virus types and subtypes in South Africa, 2009-2012(1.) *Emerg Infect Dis* 2014; 20(7): 1149-56.
187. Mahomed N, **Madhi SA**. Radiologic diagnosis of chest infection in children: WHO end-point consolidation. *Pediatr Radiol* 2014; 44 (6): 685-6.
188. Kwatra G, Adrian PV, Shiri T, Buchmann EJ, Cutland CL, **Madhi SA**. Serotype-Specific Acquisition and Loss of Group B Streptococcus Recto-vaginal Colonization in Late Pregnancy. *PlosOne.* 2014; 9(6): e98778
189. Pretorius MA, Tempia S, Treurnicht FK, Walaza S, Cohen AL, Moyes J, Hellferscee O, Variava E, Dawood H, Chhagan M, Haffjee S, **Madhi SA**, Cohen C, Venter M. Genetic Diversity and Molecular Epidemiology of Human Rhinoviruses in South Africa. *Influenza and Other Resp Vir.* 2014; 8(5):567-573.
190. **Madhi SA**, Cutland CL, Kuwanda L, Weinberg A, Hugo A, Jones S, Adrian PV, van Niekerk N, Treurnicht F, Ortiz JR, Venter M, Violari A, Neuzil KM, Simões EAF, Klugman KP, Nunes MC. Influenza vaccination of pregnant women and protection of their infants. *New Eng J Med.* 2014; 371: 918-31.
191. Wolter N, Tempia S, Cohen C, **Madhi SA**, Venter M, Moyes J, Walaza S, Malope Kgokong B, Groome M, du Plessis M, Magomani V, Pretorius M, Hellferscee O, Dawood H, Kahn K, Variava E, Klugman KP, von Gottberg A. High nasopharyngeal pneumococcal density, increased by viral co-infection, is associated with invasive pneumococcal pneumonia. *J Infect Dis.* 2014. In press.
192. Cohen C; von Mollendorf C, de Gouveia L, Naidoo N, Meiring S, Quan S, Nokeri V, Fortuin-de Smidt M, Malope-Kgokong N, Moore D, Reubenson G, Moshe M, **Madhi SA**, Eley B, Hallbauer U, Kularatne R, Conklin L, O'Brien KL, Zell ER, Klugman KP, Whitney CG, von Gottberg A. Effectiveness of seven-valent pneumococcal conjugate vaccine (PCV-7) against invasive pneumococcal disease in HIV-infected and -uninfected children in South Africa: a matched case-control study. *Clin Infect Dis* 2014; 59 (6): 808-18.

193. Nzenze SA, Shiri T, Nunes MC, Klugman KP, Kahn K, Twine R, de Gouveia L, von Gottberg A, **Madhi SA**. Temporal association of infant immunization with pneumococcal conjugate vaccine on the ecology of *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Staphylococcus aureus* nasopharyngeal colonization in a rural South African community. *Vaccine* 2014; 32: 5520-5530.
194. Naranbhai V, Kim S, Fletcher H, Cotton MF, Violari A, Mitchell C, Nachman S, McSherry G, McShane H, Hill AVS, **Madhi SA**. The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis(TB) in the first two years of life. *BMC Medicine*. 2014 ; 12 (1):120.
195. Albrich WC, **Madhi SA**, Adrian PV, van Niekerk N, Tellesa J-N, Ebrahim N, Messaoudi M, Paranhos-Baccala G, Giersdorf S, Vernet G, Muleller B, Klugman KP. Pneumococcal colonisation density: a new marker for disease severity in adult pneumonia. *BMJ Open*. 2014; 4(8): e005953.
196. Kagina BM, Wiysonge CS, Maia L, Madhi SA, Gregory HD, Safety of licensed vaccines in HIV-infected persons: a systematic review protocol BMC Systematic Reviews. In press 2014
197. Albrich WC, Madhi SA, Adrain PV, Tellesa J-N, Paranhos-Baccala G, Klugman KP. Genomic load from sputum and nasopharyngeal swabs to diagnose pneumococcal pneumonia in HIV-infected adults. *J Clin Microb* 2014 (In press)
198. Cohen C, Walaza S, Moyes J, Groome M, Tempia S, Pretorius M, Hellferscee O, Dawood H, Chhagan M, Naby F, Haffejee S, Variava E, Kahn K, Nzenze S, Tshangela A, von Gottberg A, Wolter N, Cohen AL, Kgokong B, Venter M, **Madhi SA**. Epidemiology of viral-associated acute lower respiratory tract infection amongst children aged <5 years in a high HIV prevalence setting, South Africa, 2009-2012. *Pediatr Infect Dis J* (In press Feb 2015)
199. von Mollendorf C, Cohen C, de Gouveia L, Naidoo N, Meiring S, Quan V, Lindani S, Moore DP, Reubenson G, Moshe M, Eley B, Hallbauer UM, Finlayson H, **Madhi SA**, Conklin L, Zell ER, Klugman KP, Whitney CG, von Gottberg A. Risk factors for invasive pneumococcal disease among children <5 years of age in a high HIV-prevalence setting, South Africa, 2010 to 2012. *Pediatr Infect Dis J*. 2014 (In press)
200. von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, **Madhi SA**, Zell ER, Verani JR, O'Brien KL, Whitney CW, Klugman KP, Cohen C. Pneumococcal disease and an indirect effect of vaccination, South Africa. *New Eng J Med*. 2014 (In Press)

Submitted:

1. Walaza S; Tempia S; Dawood H; Variava E; Moyes J; Cohen AL; Wolter N; Groome M; von Mollendorf C; Kahn K; Pretorius M; Venter M; Madhi SA; Cohen C. Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed tuberculosis in South Africa, 2009-2011.

PEER REVIEWED JOURNALS ARTICLES AND RESEARCH REVIEWS (GROUP AUTHORSHIP)

1. Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien KL for the Pneumococcal Carriage Group (Pneumocarr, includes Madhi SA) (2012) The fundamental link between carriage and disease. *Expert Rev Vaccines*; 11: 841 – 855.
2. Bhat N, O'Brien KL, Karron RA, Driscoll AJ, Murdoch DR; Pneumonia Methods Working Group (includes Madhi SA) (2012) Use and evaluation of molecular diagnostics for pneumonia etiology studies. *Clin Infect Dis*; 54 Suppl 2: S153-8.
3. Murdoch DR, O'Brien KL, Driscoll AJ, Karron RA, Bhat N; Pneumonia Methods Working Group (includes Madhi SA); PERCH Core Team (2012) Laboratory methods for determining pneumonia etiology in children. *Clin Infect Dis*; 54 Suppl 2: S146-52.
4. Hammitt LL, Murdoch DR, Scott JA, Driscoll A, Karron RA, Levine OS, O'Brien KL; Pneumonia Methods Working Group (includes Madhi SA) (2012) Specimen collection for the diagnosis of pediatric pneumonia. *Clin Infect Dis*; 54 Suppl 2: S132-9.
5. Wonodi CB, Deloria-Knoll M, Feikin DR, DeLuca AN, Driscoll AJ, Moïsi JC, Johnson HL, Murdoch DR, O'Brien KL, Levine OS, Scott JA; Pneumonia Methods Working Group (includes Madhi SA) and PERCH Site Investigators (2012) Evaluation of risk factors for severe pneumonia in children: the Pneumonia Etiology Research for Child Health study. *Clin Infect Dis*; 54 Suppl 2: S124-31.
6. Deloria-Knoll M, Feikin DR, Scott JA, O'Brien KL, DeLuca AN, Driscoll AJ, Levine OS; Pneumonia Methods Working Group (includes Madhi SA) (2012) Identification and selection of cases and controls in the Pneumonia Etiology Research for Child Health project. *Clin Infect Dis*; 54 Suppl 2: S117-23.
7. Scott JA, Wonodi C, Moïsi JC, Deloria-Knoll M, DeLuca AN, Karron RA, Bhat N, Murdoch DR, Crawley J, Levine OS, O'Brien KL, Feikin DR; Pneumonia Methods Working Group (includes Madhi SA) (2012) The definition of pneumonia, the assessment of severity, and clinical standardization in the Pneumonia Etiology Research for Child Health study. *Clin Infect Dis*; 54 Suppl 2: S109-16.
8. Rudan I, Arifeen SE, Bhutta ZA, Black RE, Brooks A, Chan KY, Chopra M, Duke T, Marsh D, Pio A, Simoes EAF, Tamburlini G, Theodoratou E, Weber MW, Whitney CG, Campbell H, Qazi SA, WHO/CHNRI Expert Group on Childhood Pneumonia (includes

Madhi SA) (2011) Setting research priorities to reduce global mortality from childhood pneumonia by 2015. *PloS Med*; 8: e1001099.

9.2. CHAPTERS IN BOOKS

1. *Handbook of HIV Medicine*. 1st Edition. **Madhi SA**. Immunization of the HIV-infected child. Chapter 37. Pg 316 -322. 2002 & reprint 2003, 2004. Oxford University Press Southern Africa (Cape Town).
2. *Disease And Mortality in Sub-saharan Africa*. Jamison DT, Feachem RG, Makgoba MW, Bos ER, Baingana FK, Hofman KJ, Rogo KO (Editors). 2nd Edition; 2006. **Madhi SA** and Klugman KP. Acute Respiratory Infections. Chapter 11. Pgs 149-162. The World Bank, Washington DC.
3. *Emerging Infections 7*. WM Scheld, DC Hooper, JM Hughes (Eds.). Klugman KP and **Madhi SA**. Conjugate vaccines as probes to define the burden of pneumococcal and *Haemophilus influenzae* type b pneumonia as well as the role of viruses in the pathogenesis of pneumonia. Chapter 12. Pgs 215-224. 2006. ASM Press, Washington, DC
4. *Child health for all*. Immunizations. (ed Kibel M, Saloojee H, Westwood T). Oxford University Press, Southern Africa (Pty) Ltd. Chapter 14. 4th Edition, 2007. ISBN 978 019 576295 6
5. *Pneumococcal vaccines: The Impact of Conjugate Vaccine*. Siber GR, Klugman KP and Mäkelä HP (Eds). **Madhi SA**, Pelton SI. Epidemiology, diagnosis, and treatment of serious pneumococcal infections in children. Chapter 8. Pg 95-116. ASM Press, Washington, DC. 2008. ISBN 978-1-55581-408-3
6. *Pneumococcal vaccines: The Impact of Conjugate Vaccine*. Siber GR, Klugman KP and Mäkelä HP (Eds). Klugman KP, Cutts F, Adegbola RA, Black S, **Madhi SA**, O'Brien KL, Santosham M, Shinefield H, Sterne JAC. Meta-analysis of the efficacy of conjugate vaccine against invasive pneumococcal disease. Chapter 21. Pg 317-326. ASM Press, Washington, DC. 2008. ISBN 978-1-55581-408-3
7. *Pneumococcal vaccines: The Impact of Conjugate Vaccine*. Siber GR, Klugman KP and Mäkelä HP (Eds). **Madhi SA**, Klugman KP. Efficacy and Safety of Conjugate Pneumococcal Vaccine in the Prevention of Pneumonia. Chapter 22. Pg 327-339. ASM Press, Washington, DC. 2008. ISBN 978-1-55581-408-3
8. *Coovadia's Paediatric & Child Health. A manual for health professionals in developing countries*. DF Wittenberg (ed). **Madhi SA**. Principles of infections in children. Part 5 Pg 283-311. Oxford University Press; Southern Africa. 2009. Sixth Edition. ISBN: 978 0 19 5988437.
9. *Coovadia's Paediatric & Child Health. A manual for health professionals in developing countries*. DF Wittenberg (ed). **Madhi SA**. Systemic infections. Part 5 Pg 312-334. Oxford University Press; Southern Africa. 2009. Sixth Edition. ISBN: 978 0 19 5988437.

9.3. ACCREDITED JOURNALS- LETTERS/ EDITORIALS/ COMMENTARIES/ REPLIES

1. **Madhi SA**, Zar HJ, Saloojee H, Gray GE. Co-trimoxazole prophylaxis in African children with HIV-1. Letter: *Lancet* 2005; 365: 749-50.
2. **Madhi SA**, Albrich W. WHO guidelines for treatment of severe pneumonia. Letter: *Lancet*. 2007; 370:386-7.
3. **Madhi SA**, Levine O, Cherian T. Pneumococcal conjugate vaccine is efficacious and effective in reducing the burden of pneumonia. Letter/Reply: *Bull World Health Org*. 2008; 86: A-C.
4. Nascimento-Carvalho CM, **Madhi SA**, O. Brien KL. Is pneumonia among children in developing countries a different disease from the 1 among patients in the same age group in developed countries? Letter: *Pediatr Infect Dis J*. 2014; 33(2): 229-30.
5. **Madhi SA**, Parashar UD. 116E rotavirus vaccine development: a successful alliance. Invited commentary: *Lancet* 2014. 383: 2106-7.